Nine out of 10 prescriptions are filled by generic drugs — FDA-approved carbon copies of brand-name drugs with expired patents. Over the last 30 years, generic drugs have saved trillions of dollars for hundreds of millions of people. But newer biologic medicines, including blockbuster treatments for diabetes, cancer, and autoimmune disease, are harder to manufacture into generic form. Unlike traditional “small molecule” drugs made from chemicals, biologics are large, protein-sized molecules made in living cells. Their equivalents, called biosimilars, are close but not identical copies. Now, a study from UC San Francisco researchers shows that the regulations for biosimilars vary around the world, slowing their development and adoption.

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) in Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors. The results show overall good tolerability and clear signs of effectiveness of this novel immunotherapy. They are published in the renowned scientific journal Nature Medicine.

CHICAGO, MAY 31, 2026 ― Updated results from the Phase 3 BREAKWATER trial, led by researchers at The University of Texas MD Anderson Cancer Center, demonstrated a 56% reduction in the risk of disease progression or death for patients with BRAF V600E mutant metastatic colorectal cancer treated with a targeted therapy combination.